Full Year 2025 Hikma Pharmaceuticals PLC Earnings Call and Live Q&A Transcript
Key Points
- Hikma Pharmaceuticals PLC (HKMPF) has consistently delivered growth with a strong track record, achieving a five-year CAGR and maintaining EBITDA margins of 25%, outperforming many competitors.
- The company is focusing on long-term growth by increasing its R&D budget to 5-6% of sales, aiming to drive innovation and future product launches.
- Hikma Pharmaceuticals PLC (HKMPF) is implementing a decentralized decision-making structure to empower employees and enhance agility across the organization.
- The company has a strong presence in the MENA region, being the number one company in the area, and continues to expand its biosimilar portfolio with six new biosimilars signed.
- Hikma Pharmaceuticals PLC (HKMPF) is investing heavily in its injectables business, with plans to expand its ready-to-use platform and increase its CMO capabilities, positioning itself for future growth.
- The injectables business faced challenges in 2025 and 2026, with reduced CMO contributions and delays in product launches impacting growth.
- There is increased competition in certain product areas, leading to pricing pressures and margin erosion in the injectables segment.
- The company is undergoing a period of heavy investment, which may impact short-term profitability and extend beyond the initially planned two-year period.
- Hikma Pharmaceuticals PLC (HKMPF) has faced delays in equipment and facility upgrades, particularly affecting its Bedford site, which is crucial for expanding US manufacturing capabilities.
- The company has experienced setbacks in its nasal epinephrine product launch, requiring additional studies and regulatory approvals, delaying its market entry.
Okay. Good morning, everyone. I'm Guy Featherstone, Investor Relations. Before we start, I'd like to remind you that any forward-looking statements or projections made by Hikma during this call are made in good faith based on information currently available and are subject to risks and uncertainties that may cause actual results to differ materially from those projected. For further information, please see the Principal Risks and Uncertainties section in Hikma's annual report.
Thank you for joining this Q&A meeting for Hikma's 2025 full year results. Our pre-recorded presentation is available on our website, and this will be a Q&A session. We're joined today by Said Darwazah, CEO; Mazen Darwazah, Executive Vice Chairman and Deputy CEO; Khalid Nabilsi, Deputy CEO, North America and Europe; Hafrun Fridriksdottir, President, US and Global Head of R&D. We're also joined by John Kafer, who heads up the US Injectables Commercial Business. And we have Arab Curdy recently appointed acting CFO; and Susan Ringdal, Investor
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
